Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Gastrointestinal tumours, non-colorectal

2143 - YOSEMITE: A 3 Arm Double-Blind Randomized Phase 2 Study of Gemcitabine, Paclitaxel Protein-Bound Particles for Injectable Suspension (Abraxane®) and Placebo (GAP) versus Gemcitabine, Abraxane® and either 1 or 2 Truncated Courses of Demcizumab (GAD).


11 Sep 2017


Gastrointestinal tumours, non-colorectal


Antonio Cubillo Gracian


Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369


A. Cubillo Gracian1, A. Dean2, A. Muñoz3, M. Hidalgo1, R. Pazo-Cid4, M. Martin5, T. Macarulla Mercade6, L. Lipton7, M. Harris8, J.L. Manzano-Mozo9, J. Maurel10, C. Guillen-Ponce11, N. Tebbutt12, P. Cooray13, D. Sohal14, M. Zalupski15, T. Kolevska16, R. Stagg17, D. Goldstein18

Author affiliations

  • 1 Medical Oncology, Hospedal Universitario HM Sanchinarrio, 28050 - Madrid/ES
  • 2 Medical Oncology, Saint John of God Hospital Subiaco, 6008 - Subiaco/AU
  • 3 Medical Oncology Department, Hospital General Universitario Gregorio Marañon, Madrid/ES
  • 4 Medical Oncology, Miguel Servet University Hospital, 50009 - Zaragoza/ES
  • 5 Medical Oncology, Hospital de La Santa Creu i Sant Pau, Sant Pau/ES
  • 6 Medical Oncology, Vall d`Hebron Institute of Oncology (VHIO)-Cellex Center, 08035 - Barcelona/ES
  • 7 Medical Oncology, Sunshine Hospital, Melbourne/AU
  • 8 Medical Oncology, 8Monash Medical Centre, Moorabbin Campus, Monash/AU
  • 9 Medical Oncology, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, 8916 - Badalona/ES
  • 10 Oncology, Hospital Clinic y Provincial de Barcelona, 08036 - Barcelona/ES
  • 11 Medical Oncology Department, Hospital Universitario Ramon y Cajal, 28031 - Madrid/ES
  • 12 Medical Oncology, Darebin Street Specialist Medical Centre, 3084 VIC - Heidelberg/AU
  • 13 Medical Oncology, Box Hill Hospital-Eastern health, 3128 - Box Hill/AU
  • 14 Medical Oncology, Cleveland Clinic, Cleveland/US
  • 15 Medical Oncology, University of Michigan, Ann Arbor/US
  • 16 Medical Oncology, Kaiser Permanente, Vallejo/US
  • 17 Clinical Research, OncoMed Pharmaceuticals, Redwood City/US
  • 18 Medical Oncology, University of New South Wales Cancer Research Centre, 2052 - Sydney/AU


Abstract 2143


Delta-like ligand 4 (DLL4) is a ligand that activates the Notch pathway which is important for cancer stem cell (CSC) survival. Demcizumab is a humanized, anti-DLL4 antibody that has been shown using an in vivo tumorigenicity limiting dilution assay to inhibit tumor growth and decrease CSC frequency in minimally passaged human xenograft models. In addition, inhibition of DLL4 has also been shown in preclinical studies to cause dysfunctional sprouting of new vessels resulting in an antiangiogenic effect. Encouraging data from a Phase 1b study of paclitaxel protein-bound particles for injectable suspension (Abraxane®), gemcitabine and demcizumab in patients with 1st line metastatic pancreatic cancer led to this double blind randomized 3 arm placebo-controlled Phase 2 study.


Patients with metastatic pancreatic cancer were randomized (1:1:1) to 1st-line therapy with either Arm 1 - GAP, Arm 2 - GAD with a single 70 day truncated course of demcizumab or Arm 3 - GAD with two 70 day truncated courses of demcizumab (second course starting on Day 168). GA were given at usual dose & schedule, P/D was given IV on days 1 and 15 in cycles 1-3 & 7-9. The primary endpoint was progression-free survival and secondary endpoints included response, survival, safety, immunogenicity, pharmacokinetics, and biomarkers of Notch signaling and CSCs in blood, hair follicles and tumor cells. The primary study analyses compared GAP to the two pooled GAD arms.


207 patients were randomized and 204 were treated. The median age was 63, the male/female ratio was 116/88, the ECOG 0 vs 1 distribution was 98/106, the median # metastatic sites was 2 and 74% had hepatic metastases. The response/clinical benefit rates were 41.2%/70.6% and 33.1%/74.3% in the GAP and pooled GAD arms, respectively. The median progression-free survival (PFS) (mPFS) was 5.5 months in the GAP and pooled GAD arms. The interim median overall survival (OS) for the GAP and pooled GAD arms were not reached and 13.2 months (HR = 1.02), respectively. Geographic differences in OS were observed. GAD was generally well tolerated with nausea, diarrhea, anemia, peripheral edema and fatigue being the most common reported toxicities. The incidence of the Grade 3 or greater toxicities of special interest with demcizumab therapy were hypertension (7.4% vs 16.2%), pulmonary hypertension (0% vs 0.7%), heart failure (0% vs. 3.7%), and bleeding (1.5% vs. 8.1%) in the GAP and pooled GAD arms, respectively. No cases of Grade 3 heart failure or pulmonary hypertension occurred during the 2nd 70 day course of demcizumab.


The addition of either 1 or 2 truncated courses of demcizumab to 1st-line gemcitabine and Abraxane did not improve the efficacy compared to GAP in patients with 1st line metastatic pancreatic cancer. GAD therapy was generally well tolerated.

Clinical trial identification

NCT02289898 - November 10, 2014

Legal entity responsible for the study

OncoMed Pharmaceuticals


OncoMed Pharmaceuticals


R. Stagg: Employee and own stock of OncoMed. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.